Current Edition

Aduro Biotech Says All Clinical Trials Will Continue Unaltered and as Planned

Aduro Biotech (ADRO), a clinical-stage immunotherapy company, confirmed late Tuesday that it will continue all its clinical trials unaltered and as planned. The announcement comes after Aduro earlier reported that a patient developed a listeria infection while receiving CRS-207, which the company is developing as an immunotherapy for the treatment of pancreatic cancer. At the request of the patient and the investigator, the patient continues to receive study treatment. The company said it will hold a conference call tomorrow Nov. 25, 2015 at 8 am ET (5 am PST).